Reports Q2 revenue $2.49B, consensus $2.42B. “The second quarter of 2023 marked another period of strong progress across our business. We are reaching more patients globally with our cystic fibrosis medicines, advancing our late-stage clinical programs and making rapid progress across our research and development pipeline of transformative medicines,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “In the second half of the year, we look forward to expanding our leadership in CF; continuing to prepare for several near-term potential launches, starting with exa-cel; and completing major Phase 3 trials including VX-548 in acute pain and the vanzacaftor triple in cystic fibrosis.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vertex Pharmaceuticals price target raised to $400 from $350 at BofA
- Vertex Pharmaceuticals granted approval for label extension of Orkambi
- Vertex Pharmaceuticals price target raised to $340 from $305 at Morgan Stanley
- Sigilon Therapeutics downgraded to Neutral from Buy at BTIG